The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Mubucho 40 mg film-coated tablets

Zentiva k.s.PA1701/003/002

Main Information

Trade NameMubucho 40 mg film-coated tablets
Active SubstancesDasatinib
Dosage FormFilm-coated tablet
Licence HolderZentiva k.s.
Licence NumberPA1701/003/002

Group Information

ATC CodeL01XE06 dasatinib


License statusAuthorised
Licence Issued04/11/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back